Megan Edwards
Family · Lakewood, CONPI 1427674654
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Gilead at 30.8% of the total. 2025 is the largest year on record at $2,186, more than ten times the $128 reported in 2021. Among family clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $23.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$2K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$287
- AstraZeneca$182
- Pfizer$138
- plus $1K from 28 others
What the payments were for
- Food & beverage$6,793100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 61 | $2,095 |
| Viiv Healthcare Company | 59 | $1,580 |
| AbbVie | 73 | $1,292 |
| Otsuka America Pharmaceutical, Inc. | 13 | $287 |
| AstraZeneca | 11 | $182 |
| Pfizer | 7 | $138 |
| Lilly USA, LLC | 8 | $129 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $125 |
| Merck | 4 | $110 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $101 |
| Exact Sciences | 4 | $88 |
| Idorsia Pharmaceuticals US Inc | 4 | $63 |
| Vanda Pharmaceuticals Inc. | 3 | $45 |
| Exeltis, USA Inc. | 1 | $33 |
| Aimmune Therapeutics, Inc. | 2 | $31 |
| Novo Nordisk | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Boston Scientific | 1 | $25 |
| Astellas Pharma US Inc | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Alkermes, Inc. | 1 | $24 |
| Phadia US Inc. | 1 | $24 |
| Seqirus USA Inc | 1 | $21 |
| Amgen | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Organon | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,793 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 43 | $51,745 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $14,538 |
| OzempicSemaglutide | 13 | $13,208 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,651 |
| Oxycodone Hcl | 41 | $1,021 |
| Rosuvastatin Calcium | 51 | $640 |
| Omeprazole | 32 | $621 |
| Gabapentin | 38 | $573 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $422 |
| Olmesartan Medoxomil | 57 | $413 |
| Levothyroxine Sodium | 27 | $405 |
| Sucralfate | 13 | $392 |
| Fluticasone Propionate | 26 | $360 |
| Buspirone Hcl | 22 | $360 |
| Atorvastatin Calcium | 46 | $349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $129 | $51,74543 claims |
| AstraZenecaBreztri Aerosphere | $182 | $14,53822 claims |
| Novo NordiskOzempic | $29 | $13,20813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.
Other family in Lakewood
- Brenda SassenLakewood$15K
- Ashley McKillopLakewood$14K
- Terry CheungLakewood$11K
- Danielle MarstonLakewood$10K
- Elizabeth HammondLakewood$9K
- Maryann StraleyLakewood$8K
- Lee MorseLakewood$7K
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- April RossGrand Junction$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.